Intellia Therapeutics Files Q1 2025 10-Q

Ticker: NTLA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1652130

Sentiment: neutral

Topics: 10-Q, biotechnology, financials

TL;DR

Intellia Therapeutics filed its Q1 2025 10-Q. Financials and operations detailed.

AI Summary

Intellia Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 40 Erie Street, Suite 130, Cambridge, MA, reported on its financial performance and business operations. Key financial data and operational segments were detailed in the filing.

Why It Matters

This filing provides investors and stakeholders with a quarterly update on Intellia Therapeutics' financial health and operational progress, crucial for understanding the company's trajectory in the biotechnology sector.

Risk Assessment

Risk Level: medium — Biotechnology companies like Intellia Therapeutics are inherently subject to high research and development costs, regulatory hurdles, and market volatility.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The conformed period of report is 20250331, meaning the filing covers the first quarter of 2025.

What is Intellia Therapeutics' primary business classification?

Intellia Therapeutics, Inc. is classified under Standard Industrial Classification 2835: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.

Where is Intellia Therapeutics headquartered?

Intellia Therapeutics, Inc. is located at 40 Erie Street, Suite 130, Cambridge, MA 02139.

When was this 10-Q form filed with the SEC?

This 10-Q form was filed on 20250508.

What is the SEC file number for Intellia Therapeutics?

The SEC file number for Intellia Therapeutics is 001-37766.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Intellia Therapeutics, Inc. (NTLA).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing